Pharmaceuticals

Australian Patient Advocacy Organization Named a Recipient of PTC Therapeutics' 2023 STRIVE™ Award for Duchenne Muscular Dystrophy

- Grant funding will support Save our Sons Duchenne Foundation in developing a digital health app - SYDNEY, Sept. 7, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that an Australian patient advocacy organization is one of the two recipients of the company's 2023 STRI...

2023-09-07 20:00 2672

Teikoku Pharma USA announces positive topline results from Phase 2 clinical trial of TPU-006, non- opioid pain management patch in Abdominoplasty Surgery.

SAN JOSE, Sept. 6, 2023 /PRNewswire/ -- Teikoku Pharma USA, a global pharmaceutical company, today announced positive topline results from its Phase 2 proof of concept study of TPU-006, a 4-day dexmedetomidine transdermal patch for Post Surgical Pain. The double-blind, placebo-controlled, single-...

2023-09-06 20:06 2628

Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination with PEG-IFNα for the Treatment of Chronic Hepatitis B

BRII-179 (VBI-2601) as an add-on therapy to standard of care PEG-IFNα increases HBsAg loss rate at the end of treatment and 12 weeks follow up Significantly increased HBsAg seroconversion rate is strongly associated with BRII-179 treatment and correlates with the increased rate of HBsAg loss Saf...

2023-09-06 18:45 4073

Telix to Showcase New ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline at EANM

MELBOURNE, Australia, Sept. 6, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces presentations featuring the Company's theranostic programs at the 36th Annual Congress of the European Association of Nuclear Medicine (EANM) to be held inVienna from 9...

2023-09-06 14:18 2799

MedAlliance announces enrollment of First Patient in SELUTION SLR LOVE-DEB Coronary Study

GENEVA, Sept. 6, 2023 /PRNewswire/ -- The first patient has been enrolled in a UK study of large vessel de novo coronary artery disease treated with SELUTION SLR™. This is a trial initiated by physicians at the Wrightington, Wigan and Leigh Teaching Hospitals NHS Foundation Trust, which is where ...

2023-09-06 08:00 2974

MALAYSIA HEALTHCARE TRAVEL COUNCIL SELECTS MAYO CLINIC TO PROVIDE STRATEGIC COUNSEL TO FURTHER ADVANCE MEDICAL EXCELLENCE IN MALAYSIA

PUTRAJAYA, Malaysia, Sept. 5, 2023 /PRNewswire/ -- Malaysia Healthcare Travel Council (MHTC), an agency established under the purview of Ministry of Health Malaysia, has officially announced the successful establishment of a Memorandum of Understanding (MoU) with US-basedMayo Clinic

2023-09-05 22:37 3210

YS Biopharma to Participate in Citi's 18th Annual Biopharma Conference

GAITHERSBURG, Md., Sept. 5, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious di...

2023-09-05 20:30 2378

ACM Biolabs Announces Positive Topline Results from a Phase I Trial of SARS-CoV-2 Booster Vaccine ACM-001

*  Provides clinical validation for ACM Biolab's Tunable Platform ("ATP™"), ACM Biolab's proprietary polymer-based delivery platform *  ACM-001 was well tolerated at the recommended dose levels with no serious adverse events and encouraging early immunogenicity data *  ACM is in partnering d...

2023-09-05 14:00 2619

Seegene Unveils 'Open Innovation Program Powered by Seegene' in Partnership with Springer Nature

* The program is a part of the Seegene OneSystemTM business aimed at creating a 'world free from all diseases' * Collaborating with clinical researchers worldwide, Seegene will share its technologies and enable researchers to develop syndromic qPCR assays SEOUL, South Korea, Sept. 4, 2023 /PR...

2023-09-04 21:00 3461

National University Health System Launches World's First Public Hospital's Healthy Longevity Clinic at Alexandra Hospital

SINGAPORE, Sept. 2, 2023 /PRNewswire/ -- The National University Health System (NUHS), NUS Yong Loo Lin School of Medicine andAlexandra Hospital (AH ) have achieved a milestone by unveiling the world's inaugural Healthy Longevity Clinic by public healthcare. Located atSing...

2023-09-02 13:00 4699

Sirnaomics Announces Successful Phase I Clinical Study of RNAi Therapeutic STP707 for Treatment of Multiple Solid Tumors

* Six cohorts, totaling 50 late-stage cancer patients, received STP707 four times monthly by intravenous infusion at escalating dosages. * All cohorts demonstrated a strong safety profile with no dose-limiting toxicity noted for any dosing cohort and the treated patients exhibited encouraging...

2023-08-31 11:30 6402

Sirnaomics Announces 2023 Interim Results

Positive Clinical Readouts Validate Potential of Proprietary Delivery Platforms and Cement Global Leadership in RNAi Therapeutics Business Highlights Promising progress in clinical development * After an End of Phase-II meeting and with guidance from the U.S. FDA, the Group is advancing the l...

2023-08-31 10:40 5745

The Menarini Group Announces ELZONRIS® (Tagraxofusp) Designated as an Orphan Drug for BPDCN by Japanese Ministry of Health, Labor and Welfare

* Japanese Ministry of Health, Labor and Welfare grants Orphan Drug Designation to tagraxofusp for blastic plasmacytoid dendritic cell neoplasm (BPDCN) FLORENCE, Italy and NEW YORK, Aug. 30, 2023 /PRNewswire/ -- The Menarini Group ("Menarini"), a leading international pharmaceutical and diagno...

2023-08-30 23:15 3324

European Society of Cardiology Congress: Traditional Chinese Medicine Qili Qiangxin significantly reduces the risk of cardiovascular death and re-hospitalization due to heart failure

AMSTERDAM, Aug. 30, 2023 /PRNewswire/ -- The latest study indicates that adding TCM Qili Qiangxin Capsules (developed and produced by Yiling Pharmaceutical) to the standard of care for heart failure can significantly reduce the risk of re-hospitalization due to worsening heart failure and cardio...

2023-08-30 20:11 3268

Igniting Innovation, Catalyzing Changes: Bio Farma x MIT Hacking Medicine Hackathon Celebrates Success

JAKARTA, Indonesia, Aug. 30, 2023 /PRNewswire/ -- Bio Farma , Indonesia's state-owned pharmaceutical company, has successfully concluded theBio Farma x MIT Hacking Medicine on August 24 to 27, 2023 in Bali. Over the course of four days, the Hackathon oversaw 200 chos...

2023-08-30 16:16 2836

Cerecin to Present New Infantile Spasms Data at the 35th International Epilepsy Congress, Dublin 2023

* Data from the pilot study in infantile spasms showed positive outcomes. * The results will be presented by Cerecin's Chief Medical Officer, Dr. Marc Cantillon on Sunday 2nd September at 2pm (GMT+1). * The Cerecin team will be accompanied by PharmaVentures, who will be supporting Cerecin's ...

2023-08-30 00:04 2879

Viva Biotech (1873.HK) Announces 2023 Interim Results:Solid Growth in Main Business, Significant Rebound in Profitability

Highlights of the Interim Results as of June 30, 2023: * Revenue reached RMB1,142.2 million, representing a year-on-year increase of approximately 3.0% * Gross profit amounted to RMB406.0 million, representing a year-on-year increase of approximately 17.7% * Adjusted Non-IFRS net profit amo...

2023-08-29 22:38 3600

Bayer Launches Stunting Prevention Program "CETING" for Community of Cisalak, Depok

DEPOK, Indonesia, Aug. 29, 2023 /PRNewswire/ -- Bayer, a global Life Science company in health and nutrition, is taking an active role in addressing the stunting problem inIndonesia. Coinciding with Bayer's 66th year in Indonesia, Bayer launched the CETING (Prevent Stunting) program for the commu...

2023-08-29 13:53 3234

Ferinject® granted upgraded recommendations in 2023 ESC heart failure guidelines

The 2023 European Society of Cardiology (ESC) guidelines for acute and chronic heart failure (HF) include upgraded recommendations for intravenous (IV) iron supplementation, including Ferinject® (ferric carboxymaltose), for the management of iron deficiency in patients with HF. Phase IV HEART-FI...

2023-08-28 19:00 3378

Jiangsu Recbio Technology Co., Ltd. announced 2023 interim results report and latest progress

TAIZHOU, China, Aug. 28, 2023 /PRNewswire/ -- Innovative vaccine company Recbio (02179.HK) announced its latest progress and interim results for 2023. During the reporting period, the company always adhered to the mission of " Protect Human Health With Best-In-Class Vaccines", rapidly promoted pr...

2023-08-28 11:08 4907
1 ... 99100101102103104105 ... 184